Should NICE evaluate complementary and alternative medicine?
- PMID: 17347233
- PMCID: PMC1819496
- DOI: 10.1136/bmj.39122.512211.BE
Should NICE evaluate complementary and alternative medicine?
Abstract
Demand for complementary and alternative medicine is high despite limited evidence. Linda Franck and colleagues believe that a thorough review by NICE would benefit the NHS and patients, but David Colquhoun argues that it cannot afford to re-examine evidence that has shown little benefit
Conflict of interest statement
Comment in
-
Should NICE evaluate complementary and alternative medicines?BMJ. 2007 Mar 10;334(7592):507. doi: 10.1136/bmj.39122.551250.BE. BMJ. 2007. PMID: 17347234 Free PMC article.
-
Appraisals of specific treatments are needed.BMJ. 2007 Mar 24;334(7594):600. doi: 10.1136/bmj.39156.570208.FA. BMJ. 2007. PMID: 17379872 Free PMC article. No abstract available.
References
-
- Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005;294:2618-22. - PubMed
-
- Rawlins MD. 5 NICE years. Lancet 2005;365:904-8. - PubMed
-
- NICE. NICE guidance and complementary therapies: briefing note. London: NICE, 2007.
-
- Baum M, Ernst E, Lejeune S, Horneber M. Role of complementary and alternative medicine in the care of patients with breast cancer: Report of the European Society of Mastology (EUSOMA) workshop, Florence, Italy, December 2004. Eur J Cancer 2006;42:1702-10. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical